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Serum levels of β-1,3-1,6 glucan-specific antibodies and immune 
biomarkers in normal individuals
Nobunao Ikewaki, Tohru Sonoda*, Yasushi Miyazawa**, Shin Onizuka***, Masayuki Chikamori**
Abstract
   In this clinical study, we examined the serum levels of β-1,3-1,6 glucan (BG)-specific antibodies (IgG, 
IgA2 and IgM) and the peripheral blood (PB) levels of immune biomarkers, including the serum total 
immunoglobulin (IgG, IgA and IgM), interleukin-6 (IL-6), IL-12 and soluble-form CD44 (sCD44), in 15 
normal individuals, using an originally developed enzyme-linked immunoassay (EIA). We found that the 
sera of even normal healthy individuals consistently contain BG-specific IgG, IgA2 and IgM, and that the 
titers of these antibodies vary widely among individuals. However, the serum titers of BG-specific IgM 
were strongly and significantly correlated with the serum total IgM titers (r = 0.914, P < 0.001). 
Furthermore, the serum titers of BG-specific IgG were significantly correlated with the serum levels of 
sCD44 (r = 0.611, P = 0.015), and the serum titers of BG-specific IgA2 were significantly correlated with 
the serum levels of IL-6 (r = 0.588, P = 0.021). In addition, the serum titers of BG-specific IgG, IgA2 and 
IgM showed a tendency to be correlated with the serum levels of IL-12 (r = 0.449, P = 0.081; r = 0.429, P 
= 0.092; r = 0.473, P = 0.070, respectively). Taken together, these findings show that normal human sera 
consistently and naturally contain BG-specific IgG, IgA2 and IgM. Since the titers of these BG-specific 
antibodies are correlated with the serum levels of some immune biomarkers, it may be surmised that 
they are closely associated with various immunological responses in the living body to maintain a normal 
health condition.
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Introduction
   β-glucans are mainly found in the extracts of some 
species of mushrooms and in microbes, such as black 
yeast, and possess some unique immunological 
activities 1, 2). β-glucans have been shown to exert 
cytotoxic activity against cancer cells 3) accompanied 
by activating the production of interleukin-2 (IL-2), IL-6, 
IL-12, interferon-γ (IFN-γ) and tumor necrosis factor-α 
(TNF-α) 4). These findings indicate that β-glucans 
enhance the immune system underlying the activation 
of lymphocytes, monocytes, macrophages, granulocytes, 
and natural killer (NK) cells 5). In general, the anti-
cancer actions of β-glucans are not attributable to their 
direct actions on cancer cells, as is the case with 
chemical anti-cancer drugs, but depends on the 
immunological enhancement of the host, e.g., by acting 
as a biological response modifier (BRM) 3). On the other 
hand, several studies have provided evidence to 
suggest that Dectin-1 is the β-glucan receptor 6). 
   We established and succeeded in purifying β-1,3-1,6 
glucan produced by the black yeast Aureobasidium 
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pullulans (A. pullulans) strain AFO-202 using the latest 
culture technology, and examined the immunological 
actions of this β-1,3-1,6 glucan in vitro using U937, a 
human monocyte-like cell line, and human peripheral 
blood mononuclear cells (PBMCs) 1). 
   Recently, it was reported that human and animal 
sera consistently contain β-glucan-specific antibodies 7, 8). 
However, the immunological roles of these antibodies 
in the living body, in particular, the relationship 
between the β-glucan-specific antibodies and immune 
biomarkers such as various cytokines and soluble-form 
molecules (CD antigens) have not yet been examined. 
   In this clinical study, we examined the serum levels 
of β-1,3-1,6 glucan (BG)-specific antibodies (IgG, IgA2 
and IgM) and the peripheral blood (PB) levels of 
immune biomarkers, including those of serum total 
immunoglobulin (IgG, IgA and IgM), interleukin-6 (IL-6), 
IL-12 and soluble-form CD44 (sCD44), in 15 normal 
individuals, using an originally developed enzyme-
linked immunoassay (EIA) in our laboratories.
Materials and Methods
Reagents
   A β-1,3-1,6 glucan was synthesized by Sophy Co. 
(Kochi-city, Kochi) from Aureobasidium pullulans (A. 
pullulans) strain AFO-202 using the latest biological 
culture and preparation techniques, and is currently 
available commercially as a health food supplement. In 
this study, the purified β-1,3-1,6 glucan described above 
was kindly provided to us for this study by Sophy Co. 
Enzyme-linked immunoassay (EIA) kits for measuring 
the blood levels of interleukin-6 (IL-6), IL-12 (p35+p40) 
and soluble-form CD44 (sCD44) were purchased from 
Diaclone laborator ies Co . (USA) . Horseradish 
peroxidase (HRPOD)-conjugated rabbit anti-human IgG, 
HRPOD-conjugated rabbit anti-human IgM and 
HRPOD-con juga ted mouse an t i - human IgA2 
monoclonal antibody (mAb) were purchased from MBL 
Co. (Nagoya). 
Ethics statement
   The study protocol was approved by the institutional 
review boards (IRB) of Kyushu University of Health 
and Welfare and Chikamori Hospital; the IRB numbers 
were 15-048 and 161, respectively. Informed consent 
was obtained from all the donors prior to their 
participation in this study.
Processing of the blood and serum samples 
   Blood samples of 15 normal individuals (5 males, age 
38.2 ± 9.5 yr; 10 females, age 28.7 ± 5.2 yr) were 
obtained at Chikamori Hospital (Kochi-city, Kochi). The 
serum samples were prepared using the standard 
method and the sera were stored at -80℃ until use. 
Measurement of β-1,3-1,6 glucan-specific 
antibodies in the sera
   EIA plates (Sumitomo Co., Tokyo) were coated with 
1 ㎍ /mL of purified β-1,3-1,6 glucan (BG) in carbonate-
bicarbonate buffer (0.010 M NaCO3, 0.035 M NaHCO3, 
pH9.6) for 24 hr at 4℃ . The wells were washed four 
times with phosphate-buffered saline (PBS) containing 
0.05% Tween-20 (PBST) and blocked with PBST 
containing 2% BSA (BSA-PBST) for 60 min at room 
temperature. Thereafter, the wells were washed three 
times with PBST. The sera (x1,000 dilution for IgG, x50 
dilution for IgA2 and x500 dilution for IgM with 0.1% 
BSA-PBST; 50 µL) were then added to each well, 
followed by incubation of the plate for 60 min at room 
temperature with shaking. Then, the wells were 
washed five times with PBST, followed by addition of 
HRPOD-conjugated rabbit anti-human IgG, HRPOD-
conjugated mouse anti-human IgA2 mAb or HRPOD-
conjugated rabbit anti-human IgM (x5,000 dilution with 
0.1% BSA-PBST, respectively; 50 µL) to each well and 
incubation of the plate for 60 min at room temperature 
with shaking. The wells were then washed 10 times 
with PBST, followed by addition of the substrate-
chromogen (TMB; Cosmo Bio Co.; 50 µL) to each well 
and incubation of the plate for 20 min at room 
temperature with gentle shaking. The reaction was 
stopped by the addition of 0.5 M-HCl (50 µL), and the 
optical density (O.D.) was read at 450 nm using a 
multichannel EIA-microplate reader (TOSHO Co.). The 
experiment was repeated five times. The specificity 
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and precision were confirmed by a blocking test using 
purified rabbit anti-β-1,3-1,6 glucan-specific IgG 
established in our laboratories as described previously 8). 
Measurement of IL-6, IL-12 and sCD44 in the 
sera
   The measurement of IL-6, IL-12 and sCD44 in the 
serum samples was performed using an IL-6 detection 
EIA kit, IL-12 detection kit and sCD44 detection kit, 
respectively. Each of the measurements was repeated 
three times. 
Measurement of serum total IgG, IgA and IgM 
   Measurement of serum total IgG, IgA and IgM in 
the samples was outsourced to a Special Reference 
Laboratory (SRL). Each experiment was repeated three 
times.
Statistical analysis
   Data were expressed as mean ± standard deviation 
(SD). Statistical analysis of the correlations of the 
serum titers of the BG-specific antibodies (IgG, IgA2 
and IgM) with the serum total immunoglobulin (IgG, 
IgA and IgM), IL-6, IL-12 and sCD44 levels was 
performed by the Pearson correlation test. Differences 
at P < 0.05 were considered to indicate statistical 
significance.
Results and Discussion 
   First, we examined the serum titers of BG-specific 
IgG, IgA2 and IgM in 15 normal individuals using an 
originally developed enzyme-linked immunoassay 
(EIA). As shown in Figure 1, we consistently found 
that BG-specific IgG, IgA2 and IgM in the sera of the 
normal individuals with the titers varying widely 
among individuals. BG-specific IgG (δOD: 0.81 ± 0.51) 
and BG-specific IgM (δOD: 0.67 ± 0.50) occurred in 
high titers, while BG-specific IgA2 (δOD: 0.09 ± 0.07) 
occurred in low titers (Fig. 1) in the serum samples.
   Next, we examined the correlations between the 
serum titers of BG-specific IgG, IgA2 and IgM and the 
peripheral blood (PB) levels of immune biomarkers, 
including those of serum total immunoglobulin (IgG, 
IgA and IgM), IL-6, IL-12 and sCD44. Figure 2 shows 
that the serum titers of BG-specific IgM were strongly 
and significantly correlated with the serum total IgM 
titers (r = 0.914, P < 0.001). Furthermore, the serum 
titers of BG-specific IgG were significantly correlated 
with the serum levels of sCD44 (r = 0.611, P = 0.015) 
(Fig. 3), and the serum titers of BG-specific IgA2 were 
significantly correlated with the serum levels of IL-6 (r 
= 0.588, P = 0.021) (Fig. 4). In addition, the serum titers 
of BG-specific IgG, IgA2 and IgM showed a tendency 
to be correlated with the serum levels of IL-12 (r = 
0.449, P = 0.081; r = 0.429, P = 0.092; r = 0.473, P = 
0.070, respectively) (Fig. 5).
   It is common knowledge that IgM is the first 
antibody to appear as part of the immunological 
response to initial exposure to an antigen. In this study, 
since the serum titers of BG-specific IgM were 
strongly and significantly correlated with the serum 
total IgM titers, it may be surmised that BG-specific 
IgM may also play an important role in some 
immunobiological responses to maintain the health 
condition. 
   IL-6 is a cytokine produced by T-lymphocytes, 
B-lymphocytes, monocytes, fibroblasts, endothelial cells, 
etc., and plays some important roles in both natural 
and acquired immune responses; in particular, IL-6 
regulates the growth and maturation of B-lymphocytes 
to produce antibodies 9). Since the serum titers of 
BG-specific IgA2 were significantly correlated with the 
serum levels of IL-6, it is probable that BG-specific 
IgA2 influences IgA antibody production under IL-6 
action in the mucosal and gut immune systems. 
   CD44 (molecular mass approx. 80-kDa) is expressed 
on lymphocytes , macrophages , granu locytes , 
fibroblasts, endothelial cells, natural killer (NK) cells, 
etc. In particular, CD44 plays an important role in 
stimulating NK cell and lymphokine-activated killer cell 
(LAK) functions underlying IFN-γ production, 
activation cell surface antigen expression mediated by 
protein tyrosine kinase (PTK) phosphorylation and 
intracellular Ca2+ flux 10, 11). On the other hand, there are 
three types of CD44 (CD44H, CD44E and sCD44) with 
differing biological functions. The sCD44 level in the 
89
九州保健福祉大学研究紀要　19： 87〜94，2018
serum has been reported to be increased in association 
with immunological activities. Since the serum titers of 
BG-specific IgG were significantly correlated with the 
serum levels of sCD44, it is probable that BG-specific 
IgG is related to NK cell and LAK cell functions.                   
   IL-12 is a cytokine produced by the dendritic cells 
(DCs), macrophages and neutrophils in response to 
antigenic stimulation. IL-12 plays an important role in 
the activities of NK cells and cytotoxic T-lymphocytes 
(CTLs), and directly mediates enhancement of the 
cytotoxic activity of NK cells and CTLs accompanied 
by IFN-γ production 12). Since the serum titers of 
BG-specific IgG, IgA2 and IgM showed a tendency to 
be correlated with the serum levels of IL-12, it may be 
assumed that BG-specific antibodies also indirectly 
regulate NK cell and CTL functions in immune system.
   We examined the serum titers of BG-specific 
antibodies (IgG, IgA2 and IgM) in normal individuals. 
Our finding of the existence of correlations between 
the serum titers of BG-specific antibodies and the 
serum levels of various immune biomarkers strongly 
suggest the possible involvement of BG-specific 
antibodies in the regulation of the immune system. The 
detailed mechanism(s) underlying the immunological 
roles of the BG-specific antibodies in the sera of normal 
individuals remains unclear at the present time. 
   It is possible that the intestinal bacteria flora 
influence the production of these antibodies. On the 
basis of the relationships between the serum titers of 
BG-specific antibodies and the serum levels of some 
immune biomarkers, it may be considered that when 
we consume BG as a health food supplement , 
BG-specific antibodies may more effectively regulate 
the immune system in the body as a biological 
response modifier (BRM). Further analyses are needed 
to examine the detailed production mechanism(s) of 
BG-specific antibodies at the cellular and molecular 
levels and the immunological roles of these antibodies 
in the sera of normal individuals.
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Figure 1. Measurement of BG-specific IgG, IgA2 and 
IgM in the sera of 15 normal individuals. The 
measurements were performed using an originally 
developed EIA system (See Materials and Methods for 
details). Each measurement was repeated four times. 
Figure 2. Analysis of the correlations of the serum 
titers of BG-specific antibodies (IgG, IgA2 and IgM) and 
the serum total immunoglobulin (IgG, IgA and IgM) 
titers in normal individuals (n = 15). A: Correlation 
between the serum titers of BG-specific IgG and serum 
total IgG titers (r = 0.124, P = 0.639) in all normal 
individuals. B: Correlation between the serum titers of 
BG-specific IgA2 and serum total IgA titers (r = 0.347, 
P = 0.205) in all normal individuals. C: Correlation 
between the serum titers of BG-specific IgM and the 
serum total IgM titers (r = 0.914, P < 0.001) in all 
normal individuals.
 
Figure 3. Analysis of the correlations of the serum 
titers of BG-specific antibodies (IgG, IgA2 and IgM) and 
the serum levels of IL-6 in normal individuals (n = 15). 
A: Correlation between the serum titers of BG-specific 
IgG and the serum levels of IL-6 (r = 0.370, P = 0.174) 
in all normal individuals. B: Correlation between the 
serum titers of BG-specific IgA2 and the serum levels 
of IL-6 (r = 0.588, P = 0.021) in all normal individuals. 
C: Correlation between the serum titers of BG-specific 
IgM and the serum levels of IL-6 (r = 0.233, P = 
0.403) in all normal individuals. 
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Figure 4. Analysis of the correlations of the serum 
titers of BG-specific antibodies (IgG, IgA2 and IgM) and 
the serum levels of sCD44 in normal individuals (n = 
15). A: Correlation between the serum titers of 
BG-specific IgG and the serum levels of sCD44 (r = 
0.611, P = 0.015) in all normal individuals. B: 
Correlation between the serum titers of BG-specific 
IgA2 and the serum levels of sCD44 (r = 0.075, P = 
0.790) in all normal individuals. C: Correlation between 
the serum titers of BG-specific IgM and the serum 
levels of sCD44 (r = 0.050, P = 0.858) in all normal 
individuals. 
Figure 5. Analysis of the correlations of the serum 
titers of BG-specific antibodies (IgG, IgA2 and IgM) and 
the serum levels of IL-12 in normal individuals (n = 15). 
A: Correlation between the serum titers of BG-specific 
IgG and the serum levels of IL-12  (r = 0.449, P = 
0.081) in all normal individuals. B: Correlation between 
the serum titers of BG-specific IgA2 and the serum 
levels of IL-12 (r = 0.429, P = 0.092) in all normal 
individuals. C: Correlation between the serum titers of 
BG-specific IgM and the serum levels of IL-12 (r = 
473, P = 0.070) in all normal individuals. 
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健常人におけるβ-1,3-1,6 glucan特異抗体と
免疫バイオマーカーの血清レベル
池脇　信直，園田　徹 *，宮澤　靖 **，鬼塚　信 ***，近森　正幸 **
要旨
　健常人（15名）におけるβ-1,3-1,6 glucan（BG）特異抗体と免疫バイオマーカーの血清レベルを自主開発し
た酵素抗体法（enzyme immunoassay：EIA）を用いて検討した。その結果、健常人血清中には BG特異
IgG、IgA2および IgMが恒常的に存在することが分かった。次に、BG特異抗体と免疫バイオマーカーとの
相関性を検討したところ、BG特異 IgMは血清総 IgMと強い相関（r=0.914、P<0.001）を示した。また、BG
特異 IgGは可溶性 CD44（sCD44）と有意な相関（r=0.611、P=0.015）を示し、BG特異 IgA2は IL-6と有意な
相関（r = 0.588、P = 0.021）を示した。さらに、BG特異 IgG、IgA2および IgMと IL-12との相関は有意傾向
（r=0.449、P=0.081；r=0.429、P=0.092； r=0.473、P=0.070）を各々示した。以上の結果は、BG特異 IgG、
IgA2および IgM が生体恒常性維持のための免疫応答に密接に関与することを示唆している。
キーワード ：BG 特異抗体、バイオマーカー、インターロイキン 6、インターロイキン 12、可溶性 CD44
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